+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07192315

Study to Identify Predictive Biological Markers of Severe Immune-Related Side Effects in Patients Receiving Immunotherapy for Solid Tumors

Led by Assistance Publique Hopitaux De Marseille · Updated on 2026-10-28

160

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to identify biological signatures that predict severe immune-related adverse events iRAEs in patients with solid tumor malignancies treated with immune checkpoint inhibitors ICIs. These adverse events can be life-threatening and affect survival and quality of life. The study addresses the need for reliable predictive biomarkers, as current markers are insufficient for routine clinical use. The goal is to develop signatures from a combination of biological data to enable better prevention strategies. Participants will have blood, throat, skin swabs, and stool samples collected throughout treatment visits. The study involves patients receiving anti-PD1, anti-PDL1, anti-CTLA4, anti-LAG3 immunotherapies alone or in combination as standard care. Samples are collected at multiple visits, including additional collections if immune-related adverse events occur, to analyze various biological parameters such as immunomonitoring, autoimmunity, viral monitoring, microbiota, genetics, pharmacokinetics, and radiomics. Throughout the study, participants undergo assessments for safety, biological parameter changes, quality of life, and patient-reported outcomes. The primary outcome is to identify predictive signatures for severe iRAEs over a 12-month follow-up. Secondary outcomes include organ-specific signatures, response comparisons, and quality of life evaluations. The study spans from enrollment through follow-up visits with multiple sample collections and monitoring to understand and predict iRAE risks.

CONDITIONS

Brief Title

Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study)

Research Team

N

Nausicaa Malissen, dr

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here